Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura

NCT02077192 is registered in ClinicalTrials.gov with Rigel Pharmaceuticals as lead sponsor.

NCT NCT02077192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02077192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Lead sponsor
Rigel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
June 2, 2020
Enrollment
123 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura